Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?

被引：5

作者：

Ayala-de Miguel, Carlos ^{[1
]}

Jimenez-Castro, Jeronimo ^{[1
]}

Sanchez-Vegas, Adrian ^{[1
]}

Diaz-Lopez, Sebastian ^{[1
]}

Chaves-Conde, Manuel ^{[1
]}

机构：

[1] Hosp Univ Virgen Valme, Serv Oncol Med, De Cadiz Km 548,9, Seville 41014, Spain

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2024年 / 202卷

关键词：

Colorectal cancer; Third-line; TAS-102; Bevacizumab; Anti-EGFR; Regorafenib; Fruquintinib; Trastuzumab-deruxtecan; PIPAC; INTRAPERITONEAL AEROSOL CHEMOTHERAPY; BEVACIZUMAB PLUS CHEMOTHERAPY; MISMATCH REPAIR-DEFICIENT; POSITIVE SOLID TUMORS; DRUG-ELUTING BEADS; LATER-LINE THERAPY; PHASE-III TRIAL; OPEN-LABEL; 1ST-LINE TREATMENT; LIVER METASTASES;

D O I：

10.1016/j.critrevonc.2024.104454

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer remains the third most common cancer worldwide and the second cause of cancer-related death. Treatment advances and precision oncological medicine for these tumours have been stalled in comparison to those for other common tumours such as lung and breast cancer. However, the recent publication of the SUNLIGHT trial results with the trifluridine/tipiracil (TAS-102)-bevacizumab combination and the irruption of new molecular targets with guided treatments have opened new possibilities in third-line metastatic colorectal cancer management. Anti-EGFR rechallenge, anti-HER2 targeted therapies or the promising results of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC), are some of the available options that may modify what is presumably third-line colorectal treatment. Hereby, we present the evidence of the different treatment options in third-line colorectal cancer and beyond, as well as the possibilities of sequencing them.

引用

页数：16

共 128 条

[101] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial [J].

Sartore-Bianchi, Andrea ;

Trusolino, Livio ;

Martino, Cosimo ;

Bencardino, Katia ;

Lonardi, Sara ;

Bergamo, Francesca ;

Zagonel, Vittorina ;

Leone, Francesco ;

Depetris, Ilaria ;

Martinelli, Erika ;

Troiani, Teresa ;

Ciardiello, Fortunato ;

Racca, Patrizia ;

Bertotti, Andrea ;

Siravegna, Giulia ;

Torri, Valter ;

Amatu, Alessio ;

Ghezzi, Silvia ;

Marrapese, Giovanna ;

Palmeri, Laura ;

Valtorta, Emanuele ;

Cassingena, Andrea ;

Lauricella, Calogero ;

Vanzulli, Angelo ;

Regge, Daniele ;

Veronese, Silvio ;

Comoglio, Paolo M. ;

Bardelli, Alberto ;

Marsoni, Silvia ;

Siena, Salvatore .

LANCET ONCOLOGY, 2016, 17 (06) :738-746

[102] Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure [J].

Sato Y. ;

Inaba Y. ;

Ura T. ;

Nishiofuku H. ;

Yamaura H. ;

Kato M. ;

Takahari D. ;

Tanaka T. ;

Muro K. .

Journal of Gastrointestinal Cancer, 2018, 49 (2) :132-137

[103] Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial [J].

Siena, Salvatore ;

Di Bartolomeo, Maria ;

Raghav, Kanwal ;

Masuishi, Toshiki ;

Loupakis, Fotios ;

Kawakami, Hisato ;

Yamaguchi, Kensei ;

Nishina, Tomohiro ;

Fakih, Marwan ;

Elez, Elena ;

Rodriguez, Javier ;

Ciardiello, Fortunato ;

Komatsu, Yoshito ;

Esaki, Taito ;

Chung, Ki ;

Wainberg, Zev ;

Sartore-Bianchi, Andrea ;

Saxena, Kapil ;

Yamamoto, Eriko ;

Bako, Emarjola ;

Okuda, Yasuyuki ;

Shahidi, Javad ;

Grothey, Axel ;

Yoshino, Takayuki .

LANCET ONCOLOGY, 2021, 22 (06) :779-789

[104] Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study [J].

Signorelli, Carlo ;

Calegari, Maria Alessandra ;

Basso, Michele ;

Anghelone, Annunziato ;

Lucchetti, Jessica ;

Minelli, Alessandro ;

Angotti, Lorenzo ;

Zurlo, Ina Valeria ;

Schirripa, Marta ;

Chilelli, Mario Giovanni ;

Morelli, Cristina ;

Dell'Aquila, Emanuela ;

Cosimati, Antonella ;

Gemma, Donatello ;

Ribelli, Marta ;

Emiliani, Alessandra ;

Corsi, Domenico Cristiano ;

Arrivi, Giulia ;

Mazzuca, Federica ;

Zoratto, Federica ;

Morandi, Maria Grazia ;

Santamaria, Fiorenza ;

Saltarelli, Rosa ;

Ruggeri, Enzo Maria .

CURRENT ONCOLOGY, 2023, 30 (06) :5456-5469

[105] Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review [J].

Skarderud, Maria Roed ;

Polk, Anne ;

Vistisen, Kirsten Kjeldgaard ;

Larsen, Finn Ole ;

Nielsen, Dorte Lisbet .

CANCER TREATMENT REVIEWS, 2018, 62 :61-73

[106]

Sociedad Espanola de Oncologia Medica (SEOM), 2024, Las cifras del cancer en Espana 2024

[107] A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer [J].

Sonbol, Mohamad Bassam ;

Benkhadra, Raed ;

Wang, Zhen ;

Firwana, Belal ;

Walden, Daniel J. ;

Mody, Kabir ;

Hubbard, Joleen M. ;

Murad, M. Hassan ;

Ahn, Daniel H. ;

Bekaii-Saab, Tanios .

ONCOLOGIST, 2019, 24 (09) :1174-1179

[108] Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study [J].

Strickler, John H. ;

Cercek, Andrea ;

Siena, Salvatore ;

Andre, Thierry ;

Ng, Kimmie ;

Van Cutsem, Eric ;

Wu, Christina ;

Paulson, Andrew S. ;

Hubbard, Joleen M. ;

Coveler, Andrew L. ;

Fountzilas, Christos ;

Kardosh, Adel ;

Kasi, Pashtoon M. ;

Lenz, Heinz-Josef ;

Ciombor, Kristen K. ;

Elez, Elena ;

Bajor, David L. ;

Cremolini, Chiara ;

Sanchez, Federico ;

Stecher, Michael ;

Feng, Wentao ;

Bekaii-Saab, Tanios S. .

LANCET ONCOLOGY, 2023, 24 (05) :496-508

[109] Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial [J].

Subbiah, Vivek ;

Wolf, Jurgen ;

Konda, Bhavana ;

Kang, Hyunseok ;

Spira, Alexander ;

Weiss, Jared ;

Takeda, Masayuki ;

Ohe, Yuichiro ;

Khan, Saad ;

Ohashi, Kadoaki ;

Soldatenkova, Victoria ;

Szymczak, Sylwia ;

Sullivan, Loretta ;

Wright, Jennifer ;

Drilon, Alexander .

LANCET ONCOLOGY, 2022, 23 (10) :1261-1273

[110] Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study [J].

Suenaga, Mitsukuni ;

Mizunuma, Nobuyuki ;

Matsusaka, Satoshi ;

Shinozaki, Eiji ;

Ozaka, Masato ;

Ogura, Mariko ;

Yamaguchi, Toshiharu .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 :3099-3108

← 4 5 6 7 8 9 10 11 12 13 →